| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 21, 2020
FDA assigns PDUFA target action date of March 5, 2021 LAVAL, CANADA, and CAMBRIDGE, ENGLAND – September 21, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the...
-
Sep 9, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – September 9, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...
-
Sep 8, 2020
Results from pivotal phase 2/3 study met co-primary endpoints for improvement in trough plasminogen activity levels and reduction in lesion size Pending approval, potential for Ryplazim®...
-
Sep 1, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – September 1, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...
-
Aug 10, 2020
Acquisition of OXER1 R&D Program Joined the CoVIg-19 Plasma Alliance Voluntary Delisting from Toronto Stock Exchange Net loss from continuing operations for Q2 2020 reduced by approximately 80%...